Logo

Kenneth Berlin

Apr 24, 2018

Former Rosetta Genomics CEO Kenneth Berlin has been appointed president and CEO of Advaxis, effective April 23. Berlin had been president and CEO of Rosetta since 2009 before he stepped down on April 18. That firm and Genoptix have been trying to reach a deal for Genoptix's purchase of the company. Berlin previously has held executive positions at Johnson & Johnson, and J&J firms Veridex and Ortho-Clinical Diagnostics. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.